Moreover, decreased toxicity may be related to the optimal tumor specificity and T-cell homing, whereas mouse models of BRCA show that CAR T-cells target both transmembrane glycoprotein mucin 1 (MUC1) and human epidermal growth factor receptor 2 (HER2). Here, ERBB2 is linked to invasive breast carcinoma.